Effects of administration of fostamatinib on blood concentrations of Pioglitazone in healthy subjects
Study identifier:D4300C00014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects when Administered Alone and in Combination with Fostamatinib 100 mg Twice Daily
Medical condition
Rheumatoid Arthritis, Healthy Volunteers, pharmacokinetics
Phase
Phase 1
Healthy volunteers
Yes
Study drug
fostamatinib, pioglitazone
Sex
All
Actual Enrollment
15
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 Mar 2011
Primary Completion Date: 01 May 2011
Study Completion Date: 01 May 2011
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: pioglitazone | Drug: fostamatinib oral tablets, 100mg (2 X 50mg) twice daily for 8 days Drug: pioglitazone oral tablets, 30mg single dose per period |
| Experimental: pioglitazone and fostamatinib | Drug: pioglitazone oral tablets, 30mg single dose per period |
Contacts
Investigators
Principal Investigator
Mark Layton
AstraZeneca
